Celularity partners with MuseCell Innovations on U.S. manufacturing for Dezawa MuseCell platform

PUBT · 3d ago
Celularity partners with MuseCell Innovations on U.S. manufacturing for Dezawa MuseCell platform
  • Celularity entered a U.S. manufacturing collaboration with MuseCell Innovations to produce Dezawa MuseCells at its Florham Park, New Jersey facility.
  • Initial scope targets manufacturing capability for MCI-authenticated preparations, using qualified starting materials under the licensed Dezawa Method.
  • Deal also covers production of DMC-derived products, including Dezawa MuseExosomes, supported by product-specific processes, specifications, testing, and release criteria.
  • MuseCell Innovations projects the expanded relationship could drive more than $300 million in aggregate purchases from Celularity over five years.
  • Broader collaboration could add more than 200 jobs at the New Jersey site, focused on biomanufacturing, quality control, engineering, and support roles.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celularity Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260827982573) on August 27, 2026, and is solely responsible for the information contained therein.